Countries

Ecallantide

TypeName: Business Offer
Country: United States
Summary: HAE is caused by a mutation of the C1-inhibitor gene. Defective or missing C1-inhibitor permits activation of kallikrein, a protease that is responsible for liberating bradykinin from its precursor kininogen. An excess of bradykinin leads to fluid leakage from blood vessels, causing swelling of tissues typical of HAE.Ecallantide suppresses this pathogenetic mechanism by selectively and reversibly inhibiting the activity of plasma kallikrein.https://www.creative-peptides.com/product/ecallantide-item-10-101-160-33646.html
Description:
Advantages:
Comments:
RequestId: 613
Name:Cathy Miller
Telphone:
Email:contact@creative-peptides.com
United States